Raynaud Phenomenon

• Abnormal vascular smooth muscle reactivity and endothelial dysfunction: The primary abnormality in Raynaud phenomenon involves heightened sensitivity of digital vascular smooth muscle cells to vasoconstrictive stimuli. Endothelial dysfunction is central to pathogenesis, characterized by reduced production and availability of nitric oxide (NO), a potent endothelium-derived vasodilator. Cold exposure activates transient receptor potential melastatin 8 (TRPM8) channels on sensory nerves, triggering reflex sympathetic vasoconstriction, but in Raynaud phenomenon this response is pathologically exaggerated. Additionally, endothelial cells show impaired prostacyclin (PGI2) synthesis, reducing baseline vasodilation. The net effect is loss of the normal balance between vasodilation (NO, PGI2) and vasoconstriction (endothelin-1, norepinephrine), favoring excessive vasoconstriction.

• Sympathetic nervous system hyperresponsiveness and alpha-adrenergic pathway dysfunction: Patients with Raynaud phenomenon demonstrate enhanced sympathetic outflow during cold stress, mediated through alpha-2 adrenergic receptors on vascular smooth muscle. Digital arteries show increased responsiveness to norepinephrine and serotonin, partly due to upregulation of alpha-2A adrenergic receptors in the setting of chronic sympathetic activation. Serotonin, released from activated platelets and present in increased circulating levels in some secondary Raynaud cases, acts as a potent vasoconstrictor through 5-HT1D and 5-HT1B receptors on vascular smooth muscle. The exaggerated alpha-adrenergic response is not completely explained by receptor upregulation alone, suggesting downstream intracellular signaling abnormalities.

• Structural and functional vascular changes with altered rheology and thrombotic predisposition: In chronic or secondary Raynaud phenomenon, digital arteries undergo structural remodeling including increased medial smooth muscle layer thickness and intimal proliferation, reducing vessel compliance and increasing baseline resistance. This explains why vasospastic episodes become more frequent and prolonged in secondary forms. Additionally, red blood cell deformability is reduced in Raynaud phenomenon, increasing blood viscosity and reducing capillary flow; this rheological abnormality is particularly pronounced in patients with underlying connective tissue disease. Platelet hyperaggregability occurs in both primary and secondary Raynaud phenomenon, increasing thrombotic risk during ischemic episodes. Patients with secondary Raynaud phenomenon (particularly scleroderma-associated) show evidence of chronic endothelial damage with elevated circulating endothelial cells and increased markers of endothelial injury (von Willebrand factor, endothelin-1).

• Autoimmune mechanisms and immunoglobulin-mediated pathology in secondary Raynaud phenomenon: Secondary Raynaud phenomenon, particularly in scleroderma and SLE, involves pathologic autoimmune activation against vascular endothelium. Circulating immune complexes and antiendothelial cell antibodies directly damage the endothelial cell layer, triggering inflammatory infiltration and further reducing NO availability. Anticentromere antibodies (ACA) and anti-topoisomerase I (anti-Scl-70) antibodies in scleroderma correlate with more severe vasospastic disease. In SLE-associated Raynaud phenomenon, anti-Ro/SSA and anti-La/SSB antibodies correlate with disease severity. The autoimmune activation also promotes a pro-thrombotic state through tissue factor upregulation and phospholipid antibodies in some cases.

• Genetic and epigenetic factors in primary Raynaud phenomenon: Primary Raynaud phenomenon shows familial clustering in 30-50% of cases, suggesting genetic predisposition, though specific genes have not been definitively identified. Twin studies suggest heritability of 40-60%. Environmental triggers (cold, stress) interact with genetic susceptibility, supporting a multifactorial inheritance model. Epigenetic modifications affecting endothelial function genes are being explored as potential mechanisms linking genetic predisposition to phenotypic expression.

Primary (Idiopathic) Raynaud Phenomenon

Secondary Raynaud Phenomenon - Connective Tissue Diseases (Most Common Associations)

• Systemic sclerosis (scleroderma): Present in 90-95% of patients with systemic sclerosis, making it often the earliest clinical manifestation; associated with more severe vasospasm and greater risk of digital ulcers and gangrene; anti-centromere antibodies (limited scleroderma phenotype) and anti-Scl-70 antibodies associated with diffuse disease and worse vascular complications
• Systemic lupus erythematosus (SLE): Occurs in 15-30% of SLE patients; distinguished by high frequency of digital ulceration despite less severe vasospasm; associated with lupus anticoagulant and antiphospholipid antibodies conferring thrombotic risk
• Mixed connective tissue disease (MCTD): Present in up to 85% of MCTD patients; often occurs with high anti-RNP antibody titers; characterized by less severe tissue damage compared to scleroderma-associated Raynaud phenomenon
• Sjögren syndrome: Occurs in 40-50% of primary Sjögren syndrome patients; associated with anti-Ro/SSA and anti-La/SSB antibodies
• Systemic vasculitis: Including polyarteritis nodosa and other medium-to-large vessel vasculitis; distinguished from typical Raynaud phenomenon by simultaneous involvement of other organs

Secondary Raynaud Phenomenon - Occupational/Environmental and Drug-Induced Causes

• Vibration-induced white finger (VWF): Occupational exposure to vibrating tools (jackhammer, pneumatic drills, chain saws); typically affects manual workers; represents occupational disease with potential for workers' compensation claims; pathophysiology involves both sympathetic hyperreactivity and structural vascular damage from repeated vibration trauma
• Drug-induced Raynaud phenomenon: Beta-blockers (propranolol, atenolol) cause or worsen Raynaud by blocking vasodilatory beta-2 effects; ergot alkaloids (ergotamine) cause severe vasospasm; amphetamines and cocaine via sympathomimetic effects; chemotherapy agents (cisplatin, bleomycin, taxanes); interferon-alpha in patients treated for hepatitis C or malignancy; estrogen-containing contraceptives in susceptible women
• Chemotherapy-associated Raynaud phenomenon: Bleomycin particularly associated with severe secondary Raynaud phenomenon in cancer patients; gemcitabine and taxane-based regimens also implicated; sometimes precedes development of scleroderma-like illness

Secondary Raynaud Phenomenon - Arterial Occlusive and Thrombotic Diseases

• Thrombotic thrombocytopenic purpura (TTP): Can present with severe Raynaud phenomenon as part of microangiopathic hemolytic anemia syndrome; digital ischemia may presage thrombotic crisis
• Antiphospholipid syndrome: Associated with severe Raynaud phenomenon and catastrophic antiphospholipid syndrome (CAPS); increased thrombotic risk particularly in SLE patients with dual seropositivity
• Cryoglobulinemia: Most commonly mixed cryoglobulinemia (Type II), often associated with hepatitis C infection; presents with Raynaud phenomenon, purpura, and digital ulcers; distinguished by high frequency of systemic manifestations and renal involvement

Secondary Raynaud Phenomenon - Other Medical Conditions

• Hypothyroidism: Increased blood viscosity and reduced metabolic rate contribute to Raynaud phenomenon; often reversible with thyroid hormone replacement
• Paraneoplastic syndrome: Rare presentation of underlying malignancy, particularly small cell lung cancer and gastric carcinoma; typically appears with other paraneoplastic features
• Latex allergy: Documented in healthcare workers with occupational exposure; IgE-mediated hypersensitivity mechanism

Risk Factors for Severe Disease

• Female sex (female predominance in both primary and secondary forms)
• Age <30 years at symptom onset (primary) versus any age at diagnosis of secondary disease
• Positive or high-titer autoantibodies (ANA, anti-centromere, anti-Scl-70, anti-Ro/SSA, anti-RNP)
• Nailfold capillary abnormalities on videomicroscopy (specific finding in secondary disease)
• Baseline elevated inflammatory markers (ESR, CRP)
• History of digital ulcers or tissue loss
• Living in cold climate (environmental stress)

Cardinal Color Changes (Triphasic Pattern - Classic but Not Always Observed)

Symptoms Associated with Vasospastic Episodes

• Numbness and paresthesias: Occur during the ischemic (white-blue) phase due to inadequate oxygen delivery to digital nerves; often accompanied by loss of fine motor dexterity
• Pain and throbbing: Characteristically develop during the rewarming (red) phase as blood reperfuses ischemic tissues, activating nociceptors; described as burning, throbbing, or knife-like in intensity; can be severe enough to limit activity
• Stiffness and swelling: May occur during rewarming, reflecting reactive inflammation following ischemia-reperfusion injury
• Frequency and duration: Episodes typically last 15-20 minutes but range from 5 minutes to several hours depending on temperature stimulus and disease severity; primary Raynaud phenomenon episodes usually last <20 minutes while secondary forms may persist

Symptom Timing and Triggers

• Cold-triggered attacks: Exposure to cold water (washing dishes), cold air, or air conditioning; even touching cold objects with bare hands triggers attacks; some patients with severe disease develop symptoms from air-conditioned environments
• Emotionally-triggered attacks: Psychological stress, anxiety, or emotional distress causes vasospasm without cold exposure; particularly notable in primary Raynaud phenomenon; may be mediated by stress-induced catecholamine release and enhanced sympathetic tone
• Idiopathic attacks: Some episodes occur without identifiable trigger, particularly in secondary forms, reflecting baseline vascular instability

Physical Examination Findings

• Digital pallor or cyanosis during acute attack: Direct visualization during vasospastic episode confirms diagnosis; not always present if patient examined between attacks
• Normal examination between attacks: Primary Raynaud phenomenon characteristically shows completely normal interattack physical examination with no digital scarring, ulceration, or tissue loss
• Digital ulcers, scars, or tissue loss: Red flags for secondary Raynaud phenomenon indicating previous episodes of severe ischemia; healing ulcers may show white scars; look for "punched-out" ulcers at fingertip and dorsal surfaces; loss of fingertip pads represents irreversible damage
• Nailfold capillary abnormalities: Best visualized through nailfold capillaroscopy; in secondary Raynaud phenomenon associated with scleroderma, shows enlarged capillaries, capillary dropout, and tortuous vessels (scleroderma pattern); normal in primary Raynaud phenomenon
• Skin changes suggestive of connective tissue disease: Sclerodactyly (skin tightening over fingers), skin thickening, telangiectasia; facial changes of systemic sclerosis; oral ulcers or photosensitive rash suggesting SLE; dry eyes or mouth suggesting Sjögren syndrome
• Peripheral pulses: Should be normal in uncomplicated Raynaud phenomenon; absence of pulses suggests underlying arterial occlusive disease
• Trophic changes: Loss of fingertip pads, shortening of digits, resorption of distal phalanges in severe chronic disease

Important Clinical Variants

• Unilateral Raynaud phenomenon: Should raise suspicion for underlying arterial occlusive disease, thoracic outlet syndrome, or other secondary cause rather than primary Raynaud phenomenon, which is characteristically symmetric
• Raynaud phenomenon affecting toes, nose, ears: Occurs in more severe primary disease and particularly in secondary forms; systemic sclerosis frequently involves lower extremities; SLE-associated Raynaud phenomenon more often affects multiple digit sites
• Severe primary Raynaud phenomenon: Rare variant presenting with longer duration attacks, higher frequency (several daily), more severe pain, and possible early digital changes; distinguishing these patients from secondary disease can be challenging
• Neonatal presentation: Rare but reported in infants; associated with maternal anti-Ro/SSA and anti-La/SSB antibodies in neonatal lupus

Clinical History and Diagnostic Criteria

Laboratory Testing - Identifying Secondary Disease

• Antinuclear antibody (ANA) testing: Most cost-effective initial screening test; negative or low-titer ANA (<1:80) strongly favors primary Raynaud phenomenon with negative predictive value >95%; positive ANA (≥1:80) raises concern for underlying connective tissue disease and warrants further investigation with specific antibody testing; ANA with centromere pattern (homogeneous staining) suggests limited scleroderma; speckled pattern suggests mixed connective tissue disease; peripheral pattern (nucleolar) suggests systemic sclerosis

• Specific autoantibody panel (ordered if ANA positive or clinical suspicion for secondary disease):
• Anti-centromere antibody (ACA): Found in 50-70% of scleroderma patients, particularly limited cutaneous systemic

Immediate/acute measures

• Rewarming and trigger removal: place hands in warm (not hot) water, move to a warm environment, and treat the underlying trigger; most uncomplicated attacks abort within minutes.
• Critical digital ischemia (persistent pallor/cyanosis with rest pain, impending tissue loss) is a vascular emergency: hospitalize, warm the limb, provide analgesia, start a vasodilator, add antiplatelet therapy (± anticoagulation if thrombosis is documented), obtain urgent rheumatology and vascular surgery involvement, and evaluate for a superimposed thrombotic or embolic process.

Non-pharmacologic first step (all patients)

• Cold avoidance and lifestyle modification: gloves/hand warmers, whole-body warmth (core cooling drives reflex digital vasoconstriction), smoking cessation, stress reduction, and withdrawal of offending drugs — nonselective beta blockers, ergot alkaloids, triptans, sympathomimetic decongestants, amphetamines, cocaine, interferon-alpha.

First-line pharmacotherapy

• Dihydropyridine calcium channel blockers: extended-release nifedipine or amlodipine; block L-type Ca²⁺ channels in digital vascular smooth muscle, reducing frequency and severity of attacks. This is the recommended first-line drug class in the EULAR 2017 recommendations for the treatment of systemic sclerosis and in standard US rheumatology practice. Note that no dedicated US guideline for Raynaud phenomenon exists; US practice largely parallels EULAR.

Escalation / second-line

• PDE5 inhibitors: sildenafil or tadalafil; potentiate NO–cGMP signaling; EULAR endorses their use for Raynaud phenomenon and digital ulcers in systemic sclerosis.
• Topical nitrates: nitroglycerin ointment applied to the affected digit for local vasodilation.
• Other adjuncts with weaker evidence: angiotensin receptor blockers (losartan) and SSRIs (fluoxetine, when CCB-induced hypotension limits therapy).
• Low-dose aspirin: expert-opinion/practice-based only — no controlled trial support and not a EULAR recommendation; reasonable in secondary disease with macrovascular or thrombotic involvement.
• Digital ulcers / severe secondary disease: intravenous prostacyclin analogs (iloprost, or epoprostenol where iloprost is unavailable) per EULAR; endothelin receptor antagonists (bosentan) may reduce new ulcer formation but do not heal existing ulcers.

Procedural/definitive

• Botulinum toxin injection and digital (palmar) sympathectomy for refractory ischemia; debridement or amputation only for established gangrene or osteomyelitis.

Contraindicated/avoid

• Nonselective beta blockers, ergotamine, and unopposed vasoconstrictors; PDE5 inhibitors must never be combined with nitrates (profound hypotension); bosentan is teratogenic and hepatotoxic.

Complications of the disease

• Digital ulceration: repeated ischemia–reperfusion plus fixed structural narrowing produces punched-out ulcers at the fingertip pulp or over the PIP joints; signals secondary (usually scleroderma-associated) disease, never primary Raynaud.
• Critical digital ischemia and gangrene: sustained vasospasm with superimposed thrombosis causes persistent pallor/cyanosis, unremitting rest pain, and demarcated black eschar; this is an emergency requiring hospitalization, warming, vasodilator therapy, and evaluation for embolic or thrombotic sources.
• Autoamputation and digital pitting scars: chronic tissue loss with resorption of distal phalanges; radiographs may show acro-osteolysis.
• Secondary infection: an ulcer with purulence, surrounding cellulitis, fever, or exposed bone suggests soft-tissue infection or osteomyelitis — urgent; obtain imaging and culture-directed antibiotics.
• Unmasking of systemic disease: new sclerodactyly, telangiectasias, or an abnormal nailfold capillary pattern signals conversion from apparent primary to secondary Raynaud, most often systemic sclerosis.

Complications of treatment

• Dihydropyridine calcium channel blockers: arteriolar vasodilation causes headache, flushing, ankle edema, reflex tachycardia, and orthostatic hypotension; lower esophageal sphincter relaxation can worsen the reflux that scleroderma patients already have; nifedipine causes gingival hyperplasia.
• PDE5 inhibitors: headache and hypotension; co-administration with any nitrate (including topical nitroglycerin for the same digits) can precipitate life-threatening hypotension — an avoidable emergency.
• Topical nitrates: throbbing headache and tachyphylaxis with continuous use.
• Endothelin receptor antagonists (bosentan): dose-dependent hepatotoxicity requiring scheduled liver enzyme monitoring, anemia, and teratogenicity mandating contraception and pregnancy testing.
• IV prostacyclin analogs: flushing, jaw pain, headache, nausea, and hypotension during infusion.
• Sympathectomy: symptom recurrence over time; cervical (rather than digital) sympathectomy risks Horner syndrome.

• The triphasic color sequence white → blue → red (pallor, cyanosis, reactive hyperemia) is the buzzword, but many patients show only two phases — its absence does not exclude the diagnosis.
• Best next step in a new presentation: ANA plus nailfold capillaroscopy. A negative/low-titer ANA with a normal capillary pattern predicts primary disease and warrants reassurance and cold avoidance, not immunosuppression; abnormal capillaries (dilated loops, dropout, hemorrhages) plus a positive ANA predict progression to systemic sclerosis.
• The association examiners love: Raynaud phenomenon is present in nearly all patients with systemic sclerosis and is usually its first manifestation, often preceding skin changes by years. Anti-centromere → limited cutaneous disease/CREST; anti-Scl-70 → diffuse disease.
• Digital ulcers, pitting scars, or gangrene mean secondary disease by definition — primary Raynaud never causes tissue loss and has a normal exam between attacks.
• Asymmetric or unilateral involvement is a red flag: think thoracic outlet syndrome, atherosclerotic or embolic occlusion, or hypothenar hammer syndrome, not primary Raynaud. A young man using vibrating power tools = vibration-induced white finger.
• First-line drug is a dihydropyridine calcium channel blocker (extended-release nifedipine); escalate to a PDE5 inhibitor such as sildenafil, and use IV prostacyclin analogs for active digital ulcers or critical ischemia (EULAR systemic sclerosis recommendations).
• Common distractor — the drug that makes it worse: nonselective beta blockers (unopposed alpha vasoconstriction) and ergot alkaloids. Stopping the offending drug precedes adding a vasodilator. Never combine a PDE5 inhibitor with topical nitroglycerin.
• Mimics to rule out: acrocyanosis (persistent, painless, non-episodic cyanosis without a pallor phase) and pernio/chilblains (tender violaceous cold-induced plaques) — neither shows the episodic triphasic pattern.